BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 7539044)

  • 1. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
    Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
    J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
    J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen.
    Misko IS; Schmidt C; Honeyman M; Soszynski TD; Sculley TB; Burrows SR; Moss DJ; Burman K
    Clin Exp Immunol; 1992 Jan; 87(1):65-70. PubMed ID: 1370774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
    Murray RJ; Kurilla MG; Griffin HM; Brooks JM; Mackett M; Arrand JR; Rowe M; Burrows SR; Moss DJ; Kieff E
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2906-10. PubMed ID: 2158098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
    J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T lymphocyte discrimination between type A Epstein-Barr virus transformants is mapped to an immunodominant epitope in EBNA 3.
    Misko IS; Schmidt C; Moss DJ; Burrows SR; Sculley TB
    J Gen Virol; 1991 Feb; 72 ( Pt 2)():405-9. PubMed ID: 1704413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses to Epstein-Barr virus in children.
    Tamaki H; Beaulieu BL; Somasundaran M; Sullivan JL
    J Infect Dis; 1995 Sep; 172(3):739-46. PubMed ID: 7658067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
    Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
    Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component.
    Misko IS; Sculley TB; Schmidt C; Moss DJ; Soszynski T; Burman K
    Cell Immunol; 1991 Feb; 132(2):295-307. PubMed ID: 1846323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
    Brooks JM; Murray RJ; Thomas WA; Kurilla MG; Rickinson AB
    J Exp Med; 1993 Sep; 178(3):879-87. PubMed ID: 7688791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides.
    Reali E; Guerrini R; Giori B; Borghi M; Marastoni M; Tomatis R; Traniello S; Masucci MG; Gavioli R
    Clin Exp Immunol; 1996 Aug; 105(2):369-75. PubMed ID: 8706347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro.
    Morgan SM; Wilkinson GW; Floettmann E; Blake N; Rickinson AB
    J Virol; 1996 Apr; 70(4):2394-402. PubMed ID: 8642667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1.
    Stuber G; Dillner J; Modrow S; Wolf H; Székely L; Klein G; Klein E
    Int Immunol; 1995 Apr; 7(4):653-63. PubMed ID: 7547693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
    Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
    J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
    Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.
    Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows JM; Moss DJ; Misko IS
    Int Immunol; 1997 Nov; 9(11):1745-55. PubMed ID: 9418135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.